14 dec: Rias FY: Indtjeningen og udbyttet løftes
14 dec: Dong Energy sikrer sig partner til havmølleprojekt i USA
14-12-2016 13:43:46

Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine

Relateret indhold
13:01 - 
Bavarian Nordic: Amerikanere øger shortposition
11:28 - 
Aktier/middag: Pandora trækker C20 ned efter analysenot..
11:16 - 
Aktier/Sydbank: Dollarfald koster, men danske aktier er..
Relateret debat
15:50 - 
gevinst hjemtagning 
15:42 - 
Hvis man kikker på udviklingen fra den 16 til nu,..
15:31 - 
den er enelig meget stabil i et rødt marked og m..

COPENHAGEN, Denmark, December 14, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that it has completed enrollment of 400 subjects in a Phase 2 clinical study of MVA-BN® RSV, a novel, broad spectrum, vaccine candidate against RSV (respiratory syncytial virus).

The study is evaluating the safety and immunogenicity of different doses of MVA-BN RSV in healthy subjects aged 55 or older. Top-line results from the study are anticipated in mid-2017 and will provide essential information for subsequent, larger efficacy studies.

 

Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: "We are very pleased to finalize enrollment in this study. Maintaining our pace of development in this highly underserved disease area is a key priority for Bavarian Nordic. We look forward to reporting data from this study, which will not only provide additional proof of concept for our multi-targeted approach, but will also help us to better understand the dosing requirements for patients as we progress to larger studies."

About MVA-BN RSV

MVA-BN RSV represents a new vaccine approach specifically designed to target five different RSV proteins to ensure a broad immune response against both RSV subtypes (A & B). Extensive preclinical studies have shown that MVA-BN RSV induces a balanced immune response comprised of both antibodies and T cells, in a similar fashion to the natural response to an RSV infection. These results were confirmed in a Phase 1 study in healthy adults, reported in May 2016, which showed that MVA-BN RSV significantly boosted antibodies and T cells against both RSV subtypes. The vaccine was well tolerated, with no unexpected or serious adverse reactions. The vast majority of events represented local and systemic reactions typical for vaccines.

About RSV

Respiratory syncytial virus, or RSV, is the most common cause of bronchiolitis and pneumonia in infants and a significant cause of respiratory illness in older adults, resulting in a high number of hospitalizations. RSV infections are responsible each year for a similar number of deaths as the flu in children up to age 14, as well as in the elderly population. It is estimated that more than 64 million people are infected globally each year, yet unlike the flu, there is no vaccine to prevent RSV, presenting a large unmet medical need and market opportunity.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

2016-12-14-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 775160.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 sep
BAVA
Nogle gange...bare nogle gange ville jeg godt nok vaere glad og taknemmelig hvis vi ikke evig og alt..
25
25 sep
BAVA
Luk computeren ned for i dag Baron. Alt hvad du forudsiger er helt til hest... og det fryder mig!!! ..
9
25 sep
BAVA
Gør det modsatte af Baronen og bliv rig....
6
24 sep
BAVA
Ja Baronen har altid ment, at shorterne havde fat i den lange ende. (Hykleri)   Indlæg af : Baro..
6
22 sep
BAVA
Meget spændende læsning. Bl.a. kan man på s. 109 se Bavarian Nordics portefølje af prækliniske udvik..
6
22 sep
BAVA
Åhhh. Kender i det at man taler til en dør og føler sig dum. At man ikke vil gøre det igen men så ig..
6
22 sep
BAVA
Nøj er det de 4% ned du spåëde i går? Tosse,,
5
22 sep
BAVA
Den betød faktisk lidt og pointen er, at din overskrift hedder "Intet nyt" hvilket er forkert. Din..
5
20 sep
BAVA
Marc har shortet den.:)
5
07:30
BAVA
Hvis vi alle ignorerer ham, slipper vi lettest af med ham.
4

Maersk Line får endnu en godkendelse til tysk opkøb

26-09-2017 14:21:14
Maersk Line, der er rederiet under Mærsk-koncernen, har forleden fået endnu en nødvendig godkendelse i forbindelse med den milliardstore overtagelse af tyske Hamburg Süd.Senest er det myndighederne i Brasilien, der har givet deres velsignelse af købet, fremgår det af en meddelelse fra Maersk Line.Dermed har Maersk Line indhentet godkendelser fra blandt andet USA, Australien, EU, Mexico, Tyrkiet, J..

Aktier/middag: Pandora trækker C20 ned efter analysenotat

26-09-2017 11:28:27
Smykkeproducenten Pandora er med til at trække det samlede eliteindeks ned tirsdag ved middagstid, hvor også Novo Nordisk, Lundbeck og Mærsk er blandt bundaktierne.C20 Cap-indekset falder 0,8 pct. til 1179,49, og den negative stemning er dermed mere tydelig end i resten af Europa, hvor flere store indeks ligger tættere på uændret.- Danmark er lidt hårdere ramt, og det kan måske forklares med de li..

Novo/Exane: Sænker anbefaling til "neutral" fra "outperform"

26-09-2017 06:34:01
Novo Nordisk har fået sænket anbefalingen hos finanshuset Exane til "neutral" fra tidligere "outperform, skriver Bloomberg News.Kursmålet er i samme ombæring justeret til 300 kr. fra 290 kr. Det er 2,8 pct. lavere end mandagens lukkeniveau, hvor Novo-aktien endte i 308,60 kr. efter en stigning på 0,9 pct., mens det er 0,9 pct. under analytikernes konsensusgennemsnit på 302,77 kr.Inden ændringen an..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Bavarian Nordic-aktien slikker sårene efter kæmpe tab - citat
2
Pandora/Carnegie: Kampagner og fremrykkede leverancer i USA bekymrer
3
Bavarian Nordic: Amerikanere øger shortposition
4
Aktier/åbning: Novo, Pandora og Mærsk tager fokus i negativt marked
5
Aktier/middag: Pandora trækker C20 ned efter analysenotat

Relaterede aktiekurser

Bavarian Nordic A/S 271,00 -3,2% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. september 2017 16:35:26
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170926.1 - EUROWEB4 - 2017-09-26 16:35:26 - 2017-09-26 16:35:26 - 1 - Website: OKAY